Immix Biopharma, Inc. Contracts & Agreements
34 Contracts & Agreements
- Business Finance (14 contracts)
- Business Operations (8)
- Human Resources (7)
- Intellectual Property (2)
- Mergers & Acquisitions (1)
- Uncategorized (2)
- Immix Biopharma, Inc. Amended and Restated 2021 Omnibus Equity Incentive Plan (Filed With SEC on June 14, 2024)
- Certificate of Ownership and Merger (Filed With SEC on May 20, 2024)
- Underwriting Agreement dated as of February 5, 2024 between the Company and Titan Partners Group LLC (Filed With SEC on February 6, 2024)
- Immix Biopharma, Inc., Policy for the Recovery of Erroneously Awarded Incentive-Based Compensation (Filed With SEC on November 13, 2023)
- Immix Biopharma, Inc., Form of Stock Option Grant Notice and Option Agreement (Executive Officers August 2023) (Filed With SEC on November 13, 2023)
- Immix Biopharma, Inc., Form of Stock Option Grant Notice and Option Agreement (Directors August 2023) (Filed With SEC on November 13, 2023)
- Immix Biopharma, Inc., Form of Stock Option Grant Notice and Option Agreement (Effective August 2023 Yekaterina Chudnovsky Grant (16,670)) (Filed With SEC on November 13, 2023)
- Immix Biopharma, Inc., Form of Stock Option Grant Notice and Option Agreement (Effective August 2023 Yekaterina Chudnovsky Grant (20,000)) (Filed With SEC on November 13, 2023)
- Form of Securities Purchase Agreement dated August 21, 2023 (Filed With SEC on August 22, 2023)
- Form of Pre-Funded Warrant to Purchase Common Stock (Filed With SEC on August 22, 2023)
- Sales Agreement, dated July 14, 2023, by and between the Company and ThinkEquity LLC (Filed With SEC on July 14, 2023)
- Amendment to Master Services Agreement by and between the Company and Alwaysraise, LLC dated as of May 12, 2023 (Filed With SEC on May 12, 2023)
- Amendment to Employment Agreement by and between the Company and Ilya Rachman dated as of May 12, 2023 (Filed With SEC on May 12, 2023)
- Senior Unsecured Promissory Note issued by Nexcella, Inc. to Immix Biopharma, Inc. on December 21, 2022 (Filed With SEC on March 27, 2023)
- Description of the Registrants Securities (Filed With SEC on March 27, 2023)
- Sales Agreement, dated March 22, 2023, by and between the Company and ThinkEquity LLC (Filed With SEC on March 22, 2023)
- Form of Share Purchase Agreement (Filed With SEC on January 18, 2023)
- Research and License Agreement entered into on December 8, 2022 by and between Nexcella, Inc. (formerly Immix Biopharma Cell Therapy, Inc.), Hadasit Medical Research Services &... (Filed With SEC on December 14, 2022)
- Amendment to Master Services Agreement by and between the Company and Alwaysraise, LLC dated as of November 9, 2022 (Filed With SEC on November 9, 2022)
- Amendment to Employment Agreement by and between the Company and Ilya Rachman dated as of November 9, 2022 (Filed With SEC on November 9, 2022)
- Form of Representatives Warrant (Filed With SEC on May 27, 2022)
- Form of Underwriting Agreement (Filed With SEC on May 27, 2022)
- Description of the Registrants Securities (Filed With SEC on March 28, 2022)
- Form of Underwriting Agreement (Filed With SEC on October 28, 2021)
- Form of Representatives Warrant (Filed With SEC on October 28, 2021)
- Clinical Collaboration and Supply Agreement by and between the Company and BeiGene Switzerland GmbH dated August 20, 2021 (Filed With SEC on October 15, 2021)
- Specimen Stock Certificate evidencing the shares of common stock (Filed With SEC on October 6, 2021)
- Master Service Agreement by and between the Company and AxioMx, Inc. dated December 22, 2014 (Filed With SEC on October 6, 2021)
- Management Services Agreement by and between the Company and Alwaysraise LLC, dated March 18, 2021 (Filed With SEC on October 6, 2021)
- Employment Agreement by and between the Company and Ilya Rachman dated June 18, 2021 (Filed With SEC on October 6, 2021)
- 2016 Equity Incentive Plan (Filed With SEC on October 6, 2021)
- IP License Agreement by and between the Company and Immix Biopharma Australia Pty Ltd dated January 23, 2017 (Filed With SEC on October 6, 2021)
- Form of Indemnification Agreement with directors and executive officers (Filed With SEC on October 6, 2021)
- 2021 Equity Incentive Plan (Filed With SEC on October 6, 2021)
